Seroatlas · Human Serome Atlas

CPLX3

Complexin-3

Also known as: CPLX3_HUMAN, CPX-III

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8WVH0
Gene: CPLX3
Ensembl: ENSG00000213578
Chromosome: 15
Canonical length: 158 aa
Protein class: Predicted intracellular proteins

OverviewNCBI Gene

Predicted to enable SNARE binding activity. Predicted to be involved in modulation of chemical synaptic transmission; regulation of synaptic vesicle fusion to presynaptic active zone membrane; and synaptic vesicle exocytosis. Predicted to act upstream of or within regulation of neurotransmitter secretion. Predicted to be located in cytosol; plasma membrane; and synapse. Predicted to be part of SNARE complex. Predicted to be active in several cellular components, including photoreceptor ribbon synapse; presynaptic active zone membrane; and synaptic vesicle membrane. [provided by Alliance of Genome Resources, Apr 2025]

Canonical amino-acid sequenceUniProt

158 residues, UniProt reviewed canonical sequence.

>Q8WVH0|CPLX3
     1  MAFMVKTMVG GQLKNLTGSL GGGEDKGDGD KSAAEAQGMS REEYEEYQKQ LVEEKMERDA
    61  QFTQRKAERA TLRSHFRDKY RLPKNETDES QIQMAGGDVE LPRELAKMIE EDTEEEEEKA
   121  SVLGQLASLP GLNLGSLKDK AQATLGDLKQ SAEKCHVM

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CPLX3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.51
Highest tissue expression: 127 nTPM

Expression across tissuesHPA

Tissue

prostate: 127 nTPM
spleen: 118 nTPM
retina: 92 nTPM
cerebellum: 69 nTPM
heart muscle: 45 nTPM
salivary gland: 20 nTPM

Single-cell type

cone photoreceptor cells: 2.1 nCPM
prostatic glandular cells: 1.5 nCPM
retinal amacrine cells: 0.7 nCPM
retinal bipolar cells: 0.3 nCPM
brain excitatory neurons: 0.1 nCPM
brain inhibitory neurons: 0.1 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

thalamus: 39 nTPM
cerebellum: 35 nTPM
cerebral cortex: 32 nTPM
midbrain: 19 nTPM
amygdala: 16 nTPM
basal ganglia: 14 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.85
gnomAD pLI: 0.24
gnomAD missense Z: 0.51
DepMap mean gene effect: 0.07
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

insulin secretion
modulation of chemical synaptic transmission
regulation of neurotransmitter secretion
regulation of synaptic vesicle fusion to presynaptic active zone membrane
synaptic vesicle exocytosis
visual perception
synaptic vesicle tethering involved in synaptic vesicle exocytosis

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CPLX3 as an antibody target. Whether an autoantibody or antibody against CPLX3 could matter depends on whether native CPLX3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CPLX3 is annotated at the cell surface, where native CPLX3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CPLX3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...